• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Wed, 23.07.25

Search results


January 2008
Y. Shoenfeld, G. Zandman-Goddard, L. Stojanovich, M. Cutolo, H. Amital, Y. Levy, M. Abu-Shakra, O. Barzilai, Y. Berkun, M. Blank, J.F. de Carvalho, A. Doria, B. Gilburd, U. Katz, I. Krause, P. Langevitz, H. Orbach, V. Pordeus, M. Ram, E. Toubi and Y. Sherer
Y. Shoenfeld, M. Blank, M. Abu-Shakra, H. Amital, O. Barzilai, Y. Berkun, N. Bizzaro, B. Gilburd, G. Zandman-Goddard, U. Katz, I. Krause, P. Langevitz, I.R. Mackay, H. Orbach, M. Ram, Y. Sherer, E. Toubi and M.E. Gershwin
November 2007
Y. Segev, O. Lavie, Y. Goldberg, Y. Kaufman, G. Peer, S. Gips, D. Eizenberg and R. Auslander
October 2007
Y. Talmon, P. Gilbey, R. Falah, A. Samet, H. Cohen and J. Khoury
September 2007
D. Tal, P. Gilbey, R. Bar and A. Shupak

Background: Seasickness is thought to result from conflicting inputs from the vestibular, visual and somatosensory systems. The otolithic organs, which are responsible for the sensation of linear acceleration and tilt, are important in the pathogenesis of seasickness. Vestibular evoked myogenic potentials test is an objective evaluation of saccular function.

Objective: To examine whether saccular function is related to the pathogenesis of seasickness.

Methods: VEMP1 was performed in 10 subjects susceptible to seasickness and in 14 non-susceptible subjects.

Results: Bilateral VEMP responses were obtained in 7 (50%) of the non-susceptible subjects and 1 (10%) of the susceptible subjects. No differences were found between the groups in P13 and N23 wave latencies, amplitudes, N13-P23 inter-peak latencies, and peak-to-peak asymmetry ratios. More subjects in the susceptible group had asymmetry ratios > 35%.   

Conclusions: The attenuated saccular response might be explained in the context of the neural-mismatch theory and/or the subjective vertical theory, as reflecting an adaptation effort to sea conditions. A larger study is necessary to determine whether a statistically significant difference in VEMP responses exists between seasickness-susceptible and non-susceptible subjects.
 

August 2007
G. Morali, Y. Maor, R. Klar, M. Braun, Z. Ben Ari, Y. Bujanover, E. Zuckerman, S. Boger and P. Halfon

Background: The Fibrotest-Actitest™ is a six-parameter scoring system that allows quantification of liver fibrosis and inflammation. This test has been validated by several studies in hepatitis B and C viruses and alcoholic liver disease, with a high correlation between the liver biopsy and the results of the FT-AT[1] (AUROC between 0.78 and 0.95).The FT-AT was introduced in Israel (Rambam Laboratory) in March 2005.

Objectives: To assess the results of HCV[2] patients who underwent the test during the period March 2005 to February 2006.

Methods: Serum was taken and brought to the central laboratory performing the tests within 4 hours. Six parameters were evaluated using commercial kits approved by the designer of the test (Biopredictive): total bilirubin, gamma-glutamyltransferase, alpha-2 macroglobulin, haptoglobin, alanine aminotransferase, and apolipoprotein-A1. The results were sent to the website of Biopredictive (France), which provided the FT-AT score online using a patented formula.

Results: Of the 325 patients tested, only 4 were not interpretable because of hemolysis. Patients' age ranged from 7 to 72 years (median 42); 54% were female. Liver biopsy was performed in 81 patients and was compared with the results of the Fibrotest. Findings were as follows: 27% of the patients were F0, 19% F1, 20% F2, 17% F3 and 17% F4; 18% were A0, 32% A1, 28% A2 and 22% A3. The AUROC curve comparing the Fibrotest with liver biopsy with a cutoff point at F2 and A2 for significant fibrosis and inflammation was 0.85 and 0.79 respectively.

Conclusion: Fibrotest is a simple and effective method to assess liver fibrosis and inflammation and can be considered an alternative to liver biopsy in most patients with HCV.






[1] FT-AT = Fibrotest-Actitest



[2] HCV = hepatitis C virus


July 2007
T.Naftali, D.Novick, G.Gabay, M.Rubinstein, and B.Novis

Background: Crohn's disease and ulcerative colitis are inflammatory bowel diseases with an unknown etiology. Interleukin-18 is a pro-inflammatory cytokine that is up-regulated in Crohn’s disease. IL-18[1] binding protein neutralizes IL-18. The relationship of IL-18 and IL-18BP[2] and disease activity in these diseases is not fully understood.

Objectives: To investigate the correlation of IL-18 and IL-18BP with disease activity and other disease parameters in inflammatory bowel disease.

Methods: IL-18 and IL-18BP isoform α were measured in 129 patients and 10 healthy individuals. Patients' mean age was 40.5 (range 15–70 years) and 43 were women; 58 Crohn's and 28 colitis patients were in remission and 52 and 14, respectively, were in exacerbation. Twenty-three (19 and 4 respectively) were studied in both remission and exacerbation.

Results: The mean level of free IL-18 was significantly different between healthy individuals and Crohn's patients, and between Crohn's patients during exacerbation and remission (167 ± 32 vs. 471 ± 88 and 325 ± 24 pg/ml, respectively, P < 0.05). Mean level of IL-18BP was significantly different between healthy individuals and Crohn patients, and between Crohn patients during exacerbation and remission (2.1 ± 1.1, 7.5 ± 4 and 5.23 ± 2.8 ng/ml, respectively, P < 0.01). In the colitis patients, mean free IL-18 level and IL-18BP were significantly different between healthy individuals and patients, but not between disease remission and exacerbation (167 ± 32, 492 ± 247 and 451± 69 pg/ml for IL-18, and 2.1 ± 1.1, 7.69 ± 4 and 6.8 ± 7 ng/ml for IL-18BP, respectively, P = 0.05).

Conclusions: IL-18 and IL-18BP levels are higher in patients with inflammatory bowel disease compared to healthy individuals. In Crohn's disease, but not in ulcerative colitis, IL-18 (but not free IL-18) and IL-18BP levels are significantly higher during exacerbation compared to remission. This observation highlights the importance of IL-18 in the pathogenesis of inflammatory bowel diseases, especially in Crohn's disease.






[1] IL = interleukin



[2] IL-18BP = IL-18 binding protein


O.Kalter-Leibovici, A.Atamna, F.Lubin, G.Alpert, M.Gillon Keren, H.Murad A.Chetrit, D.Goffer, S.Eilat-Adar, and U.Goldbourt

Background: Arabs in Israel have high morbidity and mortality from diabetes and cardiovascular disease. Obesity is a risk factor for both conditions.

Objectives: To investigate the prevalence of obesity (body mass index > 30 kg/m2), subjects' knowledge and behaviors, and their reports on practices of health-care professionals regarding body weight among Arabs and Jews.

Methods: The study participants (n=880) were randomly sampled from the urban population of the Hadera district in Israel. Data on demographic, socioeconomic and lifestyle characteristics; reports on height, current body weight and body weight at the age of 18 years; knowledge and behavior; and health-care professionals' practices with regard to body weight were obtained by interview. Anthropometric measurements were performed subsequently.

Results: Information on BMI[1] was available on 868 participants (49% Arabs, 49% women, median age 46 years). Although the median BMI did not differ significantly between Arabs and Jews at age 18, the prevalence of current obesity was 52% in Arab women compared to 31% in Jewish women (P < 0.001), and 25% in Arab men compared to 23% in Jewish men (P = 0.6). On multivariate analysis, obesity was significantly associated with age, BMI at the age of 18 years, leisure time physical activity and cigarette smoking, but not with ethnicity. Fewer Arabs reported measuring their body weight and Arab women were less frequently advised to maintain an active lifestyle.

Conclusions: The high prevalence of obesity among Arab women may be explained by lifestyle characteristics. Prevention of obesity in Arabs should be directed at women and should start preferably before adulthood.






[1] BMI = body mass index


June 2007
A. Szalat, G. Erez, E. Leitersdorf

Background: The management of aspirin therapy before an invasive procedure poses a frequent clinical dilemma due to uncertainty regarding b[AS1] leeding versus thromboembolic risks associated with continuation or withdrawal of the drug. There is no evidence-based data to refer to.

Objectives: To assess the opinions of internal medicine physicians regarding aspirin therapy prior to an invasive procedure.

Methods: A questionnaire presenting nine hypothetical cases with different combinations of bleeding and thromboembolic risk was given to physicians in an Internal Medicine Division during a personal interview. For each case the participants had to choose between withdrawal of aspirin prior to an invasive procedure, continuation of aspirin, or substitution of low molecular weight heparin for aspirin. Results: Sixty-one physicians participated in the survey. For a patient with low thromboembolic risk, 77% (95% confidence interval 65.3–86.3%), 95% (87.2–98.7%) and 97% (89.6–99.5%) of physicians elected to discontinue aspirin prior to a low, intermediate or high bleeding risk procedure, respectively. For intermediate risk patients, 23% (95% CI[1] 13.7–34.7%), 59% (46.4–70.8%) and 74% (61.7–83.6%) would discontinue aspirin prior to a low, intermediate or high risk procedure, and 5% (95% CI 1.3–12.8%), 23% (13.7–34.7%) and 18% (9.9–29.2%) would substitute LMWH[2] for aspirin. For a patient with high thromboembolic risk, 1.6% (95% CI 0.08–7.8%), 11.5% (5.2–21.4%) and 18% (9.9–29.2%) recommended discontinuing aspirin prior to a low, intermediate or high risk procedure, respectively. In these situations, 18% (95% CI 9.9–29.2%), 53% (40.0–64.7%) and 57% (44.8–69.3%), respectively, would substitute LMWH for aspirin.

Conclusions: The results of the current investigation may help practicing physicians to decide whether to discontinue aspirin therapy prior to invasive procedures. The possible use of LMWH to replace aspirin as suggested here should be further evaluated in a controlled clinical study.

 



 



[2] LMWH = low molecular weight heparin

 [AS1]Is it the appropriate syntax ?


Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel
ניתן להשתמש בחצי המקלדת בכדי לנווט בין כפתורי הרכיב
",e=e.removeChild(e.firstChild)):"string"==typeof o.is?e=l.createElement(a,{is:o.is}):(e=l.createElement(a),"select"===a&&(l=e,o.multiple?l.multiple=!0:o.size&&(l.size=o.size))):e=l.createElementNS(e,a),e[Ni]=t,e[Pi]=o,Pl(e,t,!1,!1),t.stateNode=e,l=Ae(a,o),a){case"iframe":case"object":case"embed":Te("load",e),u=o;break;case"video":case"audio":for(u=0;u<$a.length;u++)Te($a[u],e);u=o;break;case"source":Te("error",e),u=o;break;case"img":case"image":case"link":Te("error",e),Te("load",e),u=o;break;case"form":Te("reset",e),Te("submit",e),u=o;break;case"details":Te("toggle",e),u=o;break;case"input":A(e,o),u=M(e,o),Te("invalid",e),Ie(n,"onChange");break;case"option":u=B(e,o);break;case"select":e._wrapperState={wasMultiple:!!o.multiple},u=Uo({},o,{value:void 0}),Te("invalid",e),Ie(n,"onChange");break;case"textarea":V(e,o),u=H(e,o),Te("invalid",e),Ie(n,"onChange");break;default:u=o}Me(a,u);var s=u;for(i in s)if(s.hasOwnProperty(i)){var c=s[i];"style"===i?ze(e,c):"dangerouslySetInnerHTML"===i?(c=c?c.__html:void 0,null!=c&&Aa(e,c)):"children"===i?"string"==typeof c?("textarea"!==a||""!==c)&&X(e,c):"number"==typeof c&&X(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(ea.hasOwnProperty(i)?null!=c&&Ie(n,i):null!=c&&x(e,i,c,l))}switch(a){case"input":L(e),j(e,o,!1);break;case"textarea":L(e),$(e);break;case"option":null!=o.value&&e.setAttribute("value",""+P(o.value));break;case"select":e.multiple=!!o.multiple,n=o.value,null!=n?q(e,!!o.multiple,n,!1):null!=o.defaultValue&&q(e,!!o.multiple,o.defaultValue,!0);break;default:"function"==typeof u.onClick&&(e.onclick=Fe)}Ve(a,o)&&(t.effectTag|=4)}null!==t.ref&&(t.effectTag|=128)}return null;case 6:if(e&&null!=t.stateNode)Ll(e,t,e.memoizedProps,o);else{if("string"!=typeof o&&null===t.stateNode)throw Error(r(166));n=yn(yu.current),yn(bu.current),Jn(t)?(n=t.stateNode,o=t.memoizedProps,n[Ni]=t,n.nodeValue!==o&&(t.effectTag|=4)):(n=(9===n.nodeType?n:n.ownerDocument).createTextNode(o),n[Ni]=t,t.stateNode=n)}return null;case 13:return zt(vu),o=t.memoizedState,0!==(64&t.effectTag)?(t.expirationTime=n,t):(n=null!==o,o=!1,null===e?void 0!==t.memoizedProps.fallback&&Jn(t):(a=e.memoizedState,o=null!==a,n||null===a||(a=e.child.sibling,null!==a&&(i=t.firstEffect,null!==i?(t.firstEffect=a,a.nextEffect=i):(t.firstEffect=t.lastEffect=a,a.nextEffect=null),a.effectTag=8))),n&&!o&&0!==(2&t.mode)&&(null===e&&!0!==t.memoizedProps.unstable_avoidThisFallback||0!==(1&vu.current)?rs===Qu&&(rs=Yu):(rs!==Qu&&rs!==Yu||(rs=Gu),0!==us&&null!==es&&(To(es,ns),Co(es,us)))),(n||o)&&(t.effectTag|=4),null);case 4:return wn(),Ol(t),null;case 10:return Zt(t),null;case 17:return It(t.type)&&Ft(),null;case 19:if(zt(vu),o=t.memoizedState,null===o)return null;if(a=0!==(64&t.effectTag),i=o.rendering,null===i){if(a)mr(o,!1);else if(rs!==Qu||null!==e&&0!==(64&e.effectTag))for(i=t.child;null!==i;){if(e=_n(i),null!==e){for(t.effectTag|=64,mr(o,!1),a=e.updateQueue,null!==a&&(t.updateQueue=a,t.effectTag|=4),null===o.lastEffect&&(t.firstEffect=null),t.lastEffect=o.lastEffect,o=t.child;null!==o;)a=o,i=n,a.effectTag&=2,a.nextEffect=null,a.firstEffect=null,a.lastEffect=null,e=a.alternate,null===e?(a.childExpirationTime=0,a.expirationTime=i,a.child=null,a.memoizedProps=null,a.memoizedState=null,a.updateQueue=null,a.dependencies=null):(a.childExpirationTime=e.childExpirationTime,a.expirationTime=e.expirationTime,a.child=e.child,a.memoizedProps=e.memoizedProps,a.memoizedState=e.memoizedState,a.updateQueue=e.updateQueue,i=e.dependencies,a.dependencies=null===i?null:{expirationTime:i.expirationTime,firstContext:i.firstContext,responders:i.responders}),o=o.sibling;return Mt(vu,1&vu.current|2),t.child}i=i.sibling}}else{if(!a)if(e=_n(i),null!==e){if(t.effectTag|=64,a=!0,n=e.updateQueue,null!==n&&(t.updateQueue=n,t.effectTag|=4),mr(o,!0),null===o.tail&&"hidden"===o.tailMode&&!i.alternate)return t=t.lastEffect=o.lastEffect,null!==t&&(t.nextEffect=null),null}else 2*ru()-o.renderingStartTime>o.tailExpiration&&1t)&&vs.set(e,t)))}}function Ur(e,t){e.expirationTimee?n:e,2>=e&&t!==e?0:e}function qr(e){if(0!==e.lastExpiredTime)e.callbackExpirationTime=1073741823,e.callbackPriority=99,e.callbackNode=$t(Vr.bind(null,e));else{var t=Br(e),n=e.callbackNode;if(0===t)null!==n&&(e.callbackNode=null,e.callbackExpirationTime=0,e.callbackPriority=90);else{var r=Fr();if(1073741823===t?r=99:1===t||2===t?r=95:(r=10*(1073741821-t)-10*(1073741821-r),r=0>=r?99:250>=r?98:5250>=r?97:95),null!==n){var o=e.callbackPriority;if(e.callbackExpirationTime===t&&o>=r)return;n!==Yl&&Bl(n)}e.callbackExpirationTime=t,e.callbackPriority=r,t=1073741823===t?$t(Vr.bind(null,e)):Wt(r,Hr.bind(null,e),{timeout:10*(1073741821-t)-ru()}),e.callbackNode=t}}}function Hr(e,t){if(ks=0,t)return t=Fr(),No(e,t),qr(e),null;var n=Br(e);if(0!==n){if(t=e.callbackNode,(Ju&(Wu|$u))!==Hu)throw Error(r(327));if(lo(),e===es&&n===ns||Kr(e,n),null!==ts){var o=Ju;Ju|=Wu;for(var a=Yr();;)try{eo();break}catch(t){Xr(e,t)}if(Gt(),Ju=o,Bu.current=a,rs===Ku)throw t=os,Kr(e,n),To(e,n),qr(e),t;if(null===ts)switch(a=e.finishedWork=e.current.alternate,e.finishedExpirationTime=n,o=rs,es=null,o){case Qu:case Ku:throw Error(r(345));case Xu:No(e,2=n){e.lastPingedTime=n,Kr(e,n);break}}if(i=Br(e),0!==i&&i!==n)break;if(0!==o&&o!==n){e.lastPingedTime=o;break}e.timeoutHandle=Si(oo.bind(null,e),a);break}oo(e);break;case Gu:if(To(e,n),o=e.lastSuspendedTime,n===o&&(e.nextKnownPendingLevel=ro(a)),ss&&(a=e.lastPingedTime,0===a||a>=n)){e.lastPingedTime=n,Kr(e,n);break}if(a=Br(e),0!==a&&a!==n)break;if(0!==o&&o!==n){e.lastPingedTime=o;break}if(1073741823!==is?o=10*(1073741821-is)-ru():1073741823===as?o=0:(o=10*(1073741821-as)-5e3,a=ru(),n=10*(1073741821-n)-a,o=a-o,0>o&&(o=0),o=(120>o?120:480>o?480:1080>o?1080:1920>o?1920:3e3>o?3e3:4320>o?4320:1960*Uu(o/1960))-o,n=o?o=0:(a=0|l.busyDelayMs,i=ru()-(10*(1073741821-i)-(0|l.timeoutMs||5e3)),o=i<=a?0:a+o-i),10 component higher in the tree to provide a loading indicator or placeholder to display."+N(i))}rs!==Zu&&(rs=Xu),l=yr(l,i),f=a;do{switch(f.tag){case 3:u=l,f.effectTag|=4096,f.expirationTime=t;var w=Ar(f,u,t);ln(f,w); break e;case 1:u=l;var E=f.type,k=f.stateNode;if(0===(64&f.effectTag)&&("function"==typeof E.getDerivedStateFromError||null!==k&&"function"==typeof k.componentDidCatch&&(null===ms||!ms.has(k)))){f.effectTag|=4096,f.expirationTime=t;var _=Ir(f,u,t);ln(f,_);break e}}f=f.return}while(null!==f)}ts=no(ts)}catch(e){t=e;continue}break}}function Yr(){var e=Bu.current;return Bu.current=Cu,null===e?Cu:e}function Gr(e,t){eus&&(us=e)}function Jr(){for(;null!==ts;)ts=to(ts)}function eo(){for(;null!==ts&&!Gl();)ts=to(ts)}function to(e){var t=Fu(e.alternate,e,ns);return e.memoizedProps=e.pendingProps,null===t&&(t=no(e)),qu.current=null,t}function no(e){ts=e;do{var t=ts.alternate;if(e=ts.return,0===(2048&ts.effectTag)){if(t=br(t,ts,ns),1===ns||1!==ts.childExpirationTime){for(var n=0,r=ts.child;null!==r;){var o=r.expirationTime,a=r.childExpirationTime;o>n&&(n=o),a>n&&(n=a),r=r.sibling}ts.childExpirationTime=n}if(null!==t)return t;null!==e&&0===(2048&e.effectTag)&&(null===e.firstEffect&&(e.firstEffect=ts.firstEffect),null!==ts.lastEffect&&(null!==e.lastEffect&&(e.lastEffect.nextEffect=ts.firstEffect),e.lastEffect=ts.lastEffect),1e?t:e}function oo(e){var t=qt();return Vt(99,ao.bind(null,e,t)),null}function ao(e,t){do lo();while(null!==gs);if((Ju&(Wu|$u))!==Hu)throw Error(r(327));var n=e.finishedWork,o=e.finishedExpirationTime;if(null===n)return null;if(e.finishedWork=null,e.finishedExpirationTime=0,n===e.current)throw Error(r(177));e.callbackNode=null,e.callbackExpirationTime=0,e.callbackPriority=90,e.nextKnownPendingLevel=0;var a=ro(n);if(e.firstPendingTime=a,o<=e.lastSuspendedTime?e.firstSuspendedTime=e.lastSuspendedTime=e.nextKnownPendingLevel=0:o<=e.firstSuspendedTime&&(e.firstSuspendedTime=o-1),o<=e.lastPingedTime&&(e.lastPingedTime=0),o<=e.lastExpiredTime&&(e.lastExpiredTime=0),e===es&&(ts=es=null,ns=0),1u&&(c=u,u=l,l=c),c=Ue(w,l),f=Ue(w,u),c&&f&&(1!==k.rangeCount||k.anchorNode!==c.node||k.anchorOffset!==c.offset||k.focusNode!==f.node||k.focusOffset!==f.offset)&&(E=E.createRange(),E.setStart(c.node,c.offset),k.removeAllRanges(),l>u?(k.addRange(E),k.extend(f.node,f.offset)):(E.setEnd(f.node,f.offset),k.addRange(E)))))),E=[];for(k=w;k=k.parentNode;)1===k.nodeType&&E.push({element:k,left:k.scrollLeft,top:k.scrollTop});for("function"==typeof w.focus&&w.focus(),w=0;w=t&&e<=t}function To(e,t){var n=e.firstSuspendedTime,r=e.lastSuspendedTime;nt||0===n)&&(e.lastSuspendedTime=t),t<=e.lastPingedTime&&(e.lastPingedTime=0),t<=e.lastExpiredTime&&(e.lastExpiredTime=0)}function Co(e,t){t>e.firstPendingTime&&(e.firstPendingTime=t);var n=e.firstSuspendedTime;0!==n&&(t>=n?e.firstSuspendedTime=e.lastSuspendedTime=e.nextKnownPendingLevel=0:t>=e.lastSuspendedTime&&(e.lastSuspendedTime=t+1),t>e.nextKnownPendingLevel&&(e.nextKnownPendingLevel=t))}function No(e,t){var n=e.lastExpiredTime;(0===n||n>t)&&(e.lastExpiredTime=t)}function Po(e,t,n,o){var a=t.current,i=Fr(),l=su.suspense;i=jr(i,a,l);e:if(n){n=n._reactInternalFiber;t:{if(J(n)!==n||1!==n.tag)throw Error(r(170));var u=n;do{switch(u.tag){case 3:u=u.stateNode.context;break t;case 1:if(It(u.type)){u=u.stateNode.__reactInternalMemoizedMergedChildContext;break t}}u=u.return}while(null!==u);throw Error(r(171))}if(1===n.tag){var s=n.type;if(It(s)){n=Dt(n,s,u);break e}}n=u}else n=Al;return null===t.context?t.context=n:t.pendingContext=n,t=on(i,l),t.payload={element:e},o=void 0===o?null:o,null!==o&&(t.callback=o),an(a,t),Dr(a,i),i}function Oo(e){if(e=e.current,!e.child)return null;switch(e.child.tag){case 5:return e.child.stateNode;default:return e.child.stateNode}}function Ro(e,t){e=e.memoizedState,null!==e&&null!==e.dehydrated&&e.retryTime